Vitamin B12: the cobalt vitamin, its “active” form, and the fine print

The short version: Vitamin B12 is the only vitamin with a metal atom at its centre, a single cobalt held in a ring. Only bacteria and archaea can build it. Human cells use it in two working forms, methylcobalamin and adenosylcobalamin, for exactly two enzymes. Methylcobalamin is the form we stock. It gets sold as the “active” B12, but a 2015 review of the biochemistry found no good reason to think it beats the cheaper forms at fixing a shortage. It also breaks down within seconds in UV light, which matters more for anyone handling it than any marketing line does.
View Vitamin B12 & get a quote →
A vitamin with a metal in the middle
B12 started as a mystery cure. In 1926 two Boston doctors, George Minot and William Murphy, reported that patients with pernicious anaemia, then usually fatal, recovered on a diet heavy in raw liver. They shared the 1934 Nobel Prize in medicine with George Whipple for it. Nobody knew what in the liver was doing the work.
It took until 1948 for a team at Merck to crystallise the active factor and name it vitamin B12. Its shape was harder still. Dorothy Hodgkin worked it out by X-ray crystallography and published the structure in Nature in 1956, part of the work behind her 1964 Nobel Prize in chemistry. What she found was a cobalt atom sitting in a large flat ring, with one spot above the cobalt left open for different chemical groups to attach. That open spot is why there are several “B12s”.
Plants and animals can’t make any of them. Making B12 from scratch is confined to bacteria and archaea, and commercial B12 is still produced by fermenting bacteria, more than 10 tonnes a year according to a 2002 review.
Four forms on the shelf
The name on a B12 product tells you which group sits on the cobalt: a cyanide group, a hydroxyl group, a methyl group or an adenosyl group.
| Form | Where you meet it | In UV light |
|---|---|---|
| Cyanocobalamin | Supplements, fortified food | Light sensitive |
| Hydroxocobalamin | Injections in medicine | Most stable of the four |
| Methylcobalamin | Working form in cells; sold as “active” B12 | Turns to hydroxocobalamin in seconds |
| Adenosylcobalamin | Working form in mitochondria | Turns to hydroxocobalamin in seconds |
The light column comes from a 2013 Oslo study that shone UVA on all four in solution. All four were light sensitive. The two working forms went first.
What methylcobalamin does in a cell
For something with so much written about it, B12 has a short job list. In people it helps just two enzymes.
Methylcobalamin works with methionine synthase. That enzyme takes homocysteine, an amino acid the body produces as a by-product, and turns it back into methionine. In the same step it frees up a form of folate the cell needs, which is why B12 and folate keep turning up in the same papers. Adenosylcobalamin works with the second enzyme, methylmalonyl-CoA mutase, inside mitochondria, where it helps process certain fats and amino acids.
Browse the full research catalogue →
Is the “active” form better?
This is the selling point you’ll see most, and the evidence is thinner than the marketing.
A 2015 review from Aarhus University went through the biochemistry step by step. Whatever form comes in, a protein in the cell called MMACHC strips the group off the cobalt, and the cell then builds its own methylcobalamin and adenosylcobalamin from what’s left. In other words, a methyl group arriving on the outside isn’t kept. The authors concluded that supplying methylcobalamin or adenosylcobalamin is unlikely to be better than cyanocobalamin for preventing or correcting a shortage. Where they did see a clear case for one form, it was high-dose hydroxocobalamin, in rare inherited disorders of B12 handling.
A 2017 review in Integrative Medicine takes the other side. It prefers the natural forms (methyl-, hydroxo- and adenosylcobalamin) over cyanocobalamin, and suggests some people with certain gene variants may do better on one particular form, found by trial and error. It also agrees the methyl group is stripped off inside the cell. It’s a literature review, not a trial, and one author is chief medical officer of a supplement company.
Methylcobalamin as a medicine
In Japan, methylcobalamin has long been a licensed medicine (Eisai’s Methycobal, for peripheral neuropathy and B12-deficiency anaemia). Its newest approval comes from a high-dose ALS trial.
A group led from Tokushima University ran JETALS, a phase 3 trial in 130 people with early amyotrophic lateral sclerosis (ALS), the progressive nerve disease. Half got very high-dose methylcobalamin by intramuscular injection twice a week, the other half placebo, for 16 weeks. On the standard ALS function scale, the methylcobalamin group declined by 2.66 points and the placebo group by 4.63, a difference of 1.97 points. Overall adverse events were reported at similar rates in both groups. Eisai’s approval notice lists drug-related reactions in 7.7% of the methylcobalamin group vs 1.6% on placebo. Japan approved the drug, by Eisai under the name Rozebalamin, in September 2024.
Two things to keep in mind. The doses were tens of thousands of times the daily amount found in food, and the trial’s own authors describe it as a disease treatment rather than a vitamin supplement. The result covers one disease, one country’s trial, and a short window.
If you remember one thing: B12 has two jobs in a cell, the cell rebuilds the working forms itself, and the best trial for methylcobalamin is an ALS trial at doses nothing like a vitamin.
The light problem
This is the part that matters for anyone working with a vial. Methylcobalamin is a deep red solution, and UV light converts it to hydroxocobalamin within seconds in solution. There’s no obvious colour change to warn you, because both forms are red. So the vial lives in its box, out of sunlight, and comes out only for as long as it takes to use it.
Ours is a ready-made solution, so there’s no bacteriostatic water to add and no mixing step. Follow the storage line on the label. Our guide to how long a vial lasts covers the general handling questions.
Where the evidence stops
- Most B12 research is about shortage. The big body of work is on people who don’t get or absorb enough, managed by doctors. It says little about giving more to someone who already has enough.
- “Active” isn’t proven better. The biochemistry review found no clear advantage of methylcobalamin over cyanocobalamin for correcting a shortage.
- The approved use is narrow. Rozebalamin is a Japanese approval for ALS, built on one 16-week trial at very high doses.
- Light damage is silent. Breakdown in UV light happens in seconds, with no obvious colour change to warn you.
A note on framing
The human results above come from licensed medicines given under medical supervision, mostly to people who were short of B12 or had a specific disease. None of it transfers automatically to research material or to anyone’s own use. We sell to researchers, and a fact sheet from a national health body is a better read than any product page, ours included.
Where JP fits
JP Research supplies Vitamin B12 as methylcobalamin, a ready-made 10ml solution at 1000 mcg per ml, for laboratory research use only. We don’t hold an independent lab report for this one yet, so the listing says research grade rather than claim one. Orders are dispatched within 24 to 36 hours of payment. If you’re new to the site, our handling and storage guide is a good place to start.
Add Vitamin B12 to your quote →
Sources
- Minot and Murphy: Treatment of pernicious anemia by a special diet (JAMA, 1926; reprinted 1983)
- Nobel Prize in Physiology or Medicine 1934
- Rickes et al.: Crystalline vitamin B12 (Science, 1948)
- Hodgkin et al.: Structure of vitamin B12 (Nature, 1956)
- Nobel Prize in Chemistry 1964: Dorothy Crowfoot Hodgkin
- Martens et al.: Microbial production of vitamin B12 (Appl Microbiol Biotechnol, 2002)
- Juzeniene and Nizauskaite: Photodegradation of cobalamins (J Photochem Photobiol B, 2013)
- Obeid et al.: Cobalamin coenzyme forms are not likely to be superior (Mol Nutr Food Res, 2015)
- Paul and Brady: Comparative bioavailability of B12 forms (Integr Med, 2017)
- Oki et al.: Ultrahigh-dose methylcobalamin in early ALS, JETALS (JAMA Neurol, 2022)
- ClinicalTrials.gov: JETALS (NCT03548311)
- Kaji et al.: Ultra-high dose methylcobalamin for ALS, review (Curr Opin Neurol, 2024)
- Eisai: Rozebalamin approved in Japan for ALS (September 2024)
- NIH Office of Dietary Supplements: Vitamin B12 fact sheet for health professionals
All JP Research products are supplied strictly for in-vitro research and laboratory use only. They are not intended for human or animal consumption, medical treatment, or diagnostic use. Nothing in this article constitutes medical advice.